Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $195.70 | 9 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $69.68 | 3 | $0 (2024) |
| ABBVIE INC. | $51.05 | 2 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $26.23 | 1 | $0 (2024) |
| Xeris Pharmaceuticals, Inc. | $17.93 | 1 | $0 (2022) |
| PFIZER INC. | $16.20 | 1 | $0 (2024) |
| Endo USA, Inc. | $14.61 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $153.66 | 7 | ABBVIE INC. ($51.05) |
| 2023 | $24.11 | 1 | Novo Nordisk Inc ($24.11) |
| 2022 | $17.93 | 1 | Xeris Pharmaceuticals, Inc. ($17.93) |
All Payment Transactions
9 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Novo Nordisk Inc | Sogroya (Biological) | Food and Beverage | In-kind items and services | $24.34 | General |
| Category: Growth Hormone | ||||||
| 10/22/2024 | ABBVIE INC. | LUPRON DEPOT (Drug) | Food and Beverage | In-kind items and services | $27.89 | General |
| Category: ENDOCRINOLOGY | ||||||
| 08/27/2024 | PFIZER INC. | NGENLA (Drug) | Food and Beverage | In-kind items and services | $16.20 | General |
| Category: ENDOCRINE DISEASE;METABOLIC DISEASE | ||||||
| 07/22/2024 | Endo USA, Inc. | SUPPRELIN (Drug) | Food and Beverage | In-kind items and services | $14.61 | General |
| Category: ENDOCRINOLOGY | ||||||
| 04/23/2024 | Novo Nordisk Inc | Sogroya (Biological) | Food and Beverage | In-kind items and services | $21.23 | General |
| Category: Growth Hormone | ||||||
| 03/27/2024 | ABBVIE INC. | LUPRON DEPOT (Drug) | Food and Beverage | In-kind items and services | $23.16 | General |
| Category: ENDOCRINOLOGY | ||||||
| 02/26/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Food and Beverage | In-kind items and services | $26.23 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 09/22/2023 | Novo Nordisk Inc | Sogroya (Biological) | Food and Beverage | In-kind items and services | $24.11 | General |
| Category: Growth Hormone | ||||||
| 10/17/2022 | Xeris Pharmaceuticals, Inc. | GVOKE PFS (Drug) | Food and Beverage | In-kind items and services | $17.93 | General |
| Category: Diabetes | ||||||
About Dr. Sydney Middleton, MD
Dr. Sydney Middleton, MD is a Pediatric Endocrinology healthcare provider based in Charleston, South Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/04/2019. The National Provider Identifier (NPI) number assigned to this provider is 1659833937.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sydney Middleton, MD has received a total of $195.70 in payments from pharmaceutical and medical device companies, with $153.66 received in 2024. These payments were reported across 9 transactions from 6 companies. The most common payment nature is "Food and Beverage" ($195.70).
Practice Information
- Specialty Pediatric Endocrinology
- Location Charleston, SC
- Active Since 04/04/2019
- Last Updated 11/11/2025
- Taxonomy Code 2080P0205X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1659833937
Products in Payments
- Sogroya (Biological) $69.68
- LUPRON DEPOT (Drug) $51.05
- TZIELD (Biological) $26.23
- GVOKE PFS (Drug) $17.93
- NGENLA (Drug) $16.20
- SUPPRELIN (Drug) $14.61
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.